top of page
Search

Autoimmune-Summaries: Daily Autoimmune Updates at a Glance

  • decodeMR Team
  • Jun 5
  • 1 min read

04/06/2026










Gilead Sciences and Lakefront completed the acquisition of Ouro Medicines to further expand inflammation pipeline (Ref)


Gilead Sciences and Lakefront Biotherapeutics announced the successful completion of the previously announced acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases.


  • The acquisition added gamgertamig (OM336; BCMAxCD3 T cell engager) to Gilead’s growing inflammation portfolio and will be the foundation of Lakefront’s clinical development pipeline.


  • Gamgertamig was granted both Fast Track and Orphan Drug Designation by the US FDA for the treatment of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) and was expected to enter registrational studies as early as 2027.


bottom of page